Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of MD1003 (high-dose biotin) in amyotrophic lateral sclerosis
2015-005810-31Phase 2Completed
- Sponsor
- MedDay Pharmaceuticals
- Start
- Oct 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing MD1003 (biotin) with Placebo (2 arms). Primary endpoint: Safety. Started Oct 2016; status: completed.
02
Drugs
biotin
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2015-005810-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005810-31.